Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

ASO Visual Abstract: Neuron-Associated Transcriptional Enrichment Is Associated with Distinct Biological States and Predicts Poor Prognosis in Gastric Cancer.

Annals of surgical oncology·2026

Same author

The clinical relevance of apocrine morphology in breast cancer depends on the estrogen receptor status.

NPJ breast cancer·2026

Same author

The development of Breast Apocrine Carcinoma (BAC) score that distinguishes breast and cutaneous apocrine carcinomas.

Research square·2026

Same author

ASO Author Reflections: Neuronal Signature Enrichment Distinguishes a Type of Gastric Cancer with Poor Prognosis.

Annals of surgical oncology·2026

Same author

Residual disease after neoadjuvant therapy in HER2-positive breast cancer: biology, burden, or both?

Translational cancer research·2026

Same author

TP53 mutation is associated with shorter treatment duration with CDK4/6 inhibitors, but not with immune checkpoint inhibitors, in ER-positive/HER2-negative breast cancer: real-world perspective.

Breast cancer research : BCR·2026

Search research articles

Related Experiment Video

Updated: May 31, 2026

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Published on: June 8, 2022

Targeting sphingosine-1-phosphate in hematologic malignancies.

Christina E Stevenson¹, Kazuaki Takabe, Masayuki Nagahashi

¹Division of Surgical Oncology, Department of Surgery, Virginia Commonwealth University School of Medicine, Richmond, 23298-0614, USA.

Anti-Cancer Agents in Medicinal Chemistry

|June 29, 2011

Summary

Sphingosine-1-phosphate (S1P) is crucial in blood cancers. Targeting Sphingosine kinase 1 (SphK1) and its signaling pathway, including the drug FTY720, shows promise for treating hematologic malignancies.

More Related Videos

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Related Experiment Videos

Last Updated: May 31, 2026

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Published on: June 8, 2022

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Area of Science:

Biochemistry
Cell Biology
Oncology

Background:

Sphingosine-1-phosphate (S1P) is a lipid mediator regulating key processes in hematologic cancer progression.
S1P is synthesized by sphingosine kinases (SphK1 and SphK2) and acts extracellularly via G-protein coupled receptors, termed 'inside-out signaling'.

Purpose of the Study:

This review highlights the critical role of SphK1 and S1P-mediated inside-out signaling in hematologic malignancies.
It summarizes research on targeting the SphK1/S1P/S1P receptor axis in blood cancers.

Main Methods:

Literature review focusing on the SphK1/S1P pathway.
Analysis of studies investigating S1P receptor modulators, such as FTY720, in hematologic cancers.

Main Results:

SphK1 and inside-out signaling are important drivers of hematologic malignancy.
Targeting this axis and using S1P receptor modulators like FTY720 demonstrates therapeutic potential.

Conclusions:

The SphK1/S1P/S1P receptor axis represents a significant therapeutic target in hematologic cancers.
Further investigation into S1P pathway modulators may lead to novel treatment strategies.